In this study, we developed an Anap-based labeling platform optimized for minimally disruptive labeling of two important proteins, G3BP1 and TDP-43, involved in membraneless organelles and neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). This evidence concerns the gene TARDBP and frontotemporal dementia.